D&D Pharmatech signs research service contract with Pfizer for obesity drug formulation development, boosting revenue and credibility
D&D Pharmatech has entered into a research service contract with global pharmaceutical giant Pfizer Inc. for the formulation development of an oral peptide dual agonist obesity treatment. The contract value is approximately 1.83 billion KRW, representing 42.64% of the company's 2025 consolidated revenue.
This contract validates D&D Pharmatech's technological capabilities and provides a stable revenue stream while establishing a partnership with a top-tier pharma company. However, the contract size is relatively small compared to the market cap, limiting short-term stock price impact.
There are no changes in capital structure or share buyback/cancellation. The contract period runs from April to November 2026.
[AI Summary]D&D Pharmatech's service contract with Pfizer diversifies revenue and validates technology, but the small scale minimizes immediate shareholder value impact. The collaboration with a highly credible counterparty supports long-term growth prospects.